{"protocolSection": {"identificationModule": {"nctId": "NCT01318109", "orgStudyIdInfo": {"id": "SYR-322/CCT-006"}, "secondaryIdInfos": [{"id": "JapicCTI-080629", "type": "REGISTRY", "domain": "JapicCTI"}, {"id": "UMIN000001394", "type": "REGISTRY", "domain": "UMIN-CTR"}, {"id": "U1111-1119-6303", "type": "REGISTRY", "domain": "WHO"}], "organization": {"fullName": "Takeda", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan", "officialTitle": "A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Metformin in Subjects With Type 2 Diabetes in Japan"}, "statusModule": {"statusVerifiedDate": "2012-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-08"}, "primaryCompletionDateStruct": {"date": "2009-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-03-16", "studyFirstSubmitQcDate": "2011-03-17", "studyFirstPostDateStruct": {"date": "2011-03-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-06-08", "resultsFirstSubmitQcDate": "2011-06-08", "resultsFirstPostDateStruct": {"date": "2011-07-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-02-01", "lastUpdatePostDateStruct": {"date": "2012-02-03", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Takeda", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study was evaluate the efficacy and safety of alogliptin, once dairy (QD) combined with metformin taken twice daily (BID) or three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.", "detailedDescription": "Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.\n\nTakeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes.\n\nThe present study was planned to evaluate the efficacy and safety of alogliptin as an add-on to metformin in type 2 diabetic patients who have uncontrolled blood glucose despite treatment with metformin as well as diet and exercise therapies."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Diabetes Mellitus - Type 2", "Diabetes Mellitus", "Drug Therapy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 288, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Alogliptin 12.5 mg QD and metformin 500mg BID or 750mg TID", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Alogliptin and metformin"]}, {"label": "Alogliptin 25mg QD and metformin 500mg BID or 750mg TID", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Alogliptin and metformin"]}, {"label": "Metformin 500mg BID or 750mg TID", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Alogliptin and metformin", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.", "armGroupLabels": ["Alogliptin 12.5 mg QD and metformin 500mg BID or 750mg TID"], "otherNames": ["SYR-32", "Glycoran"]}, {"type": "DRUG", "name": "Alogliptin and metformin", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.", "armGroupLabels": ["Alogliptin 25mg QD and metformin 500mg BID or 750mg TID"], "otherNames": ["SYR-322", "Glycoran"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.", "armGroupLabels": ["Metformin 500mg BID or 750mg TID"], "otherNames": ["Glycoran"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 12).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 12."}], "secondaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 2).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 2."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 4).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 4."}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (Week 8).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.", "timeFrame": "Baseline and Week 8."}, {"measure": "Change From Baseline in Fasting Plasma Glucose (Week 2).", "description": "The change between the value of fasting plasma glucose collected at week 2 and baseline.", "timeFrame": "Baseline and Week 2."}, {"measure": "Change From Baseline in Fasting Plasma Glucose (Week 4).", "description": "The change between the value of fasting plasma glucose collected at week 4 and baseline.", "timeFrame": "Baseline and Week 4."}, {"measure": "Change From Baseline in Fasting Plasma Glucose (Week 8).", "description": "The change between the value of fasting plasma glucose collected at week 8 and baseline.", "timeFrame": "Baseline and Week 8."}, {"measure": "Change From Baseline in Fasting Plasma Glucose (Week 12).", "description": "The change between the value of fasting plasma glucose collected at week 12 or final visit and baseline.", "timeFrame": "Baseline and Week 12."}, {"measure": "Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).", "description": "The change between the value of blood glucose measured by the meal tolerance test collected at week 12 or final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.", "timeFrame": "Baseline and Week 12."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Had been taking metformin at a stable dose regimen (500 mg/day twice daily after meal or 750 mg/day three times daily after meal) for at least 12 weeks prior to the initiation of the treatment period (Week 0).\n2. Had an glycosylated hemoglobin (HbA1c) of 6.5% or more and below 10.0% at 8 weeks after the initiation of the observation period (Week -4).\n3. Had an HbA1c difference between 4 weeks after the initiation of the observation period (Week -8) and 8 weeks after the initiation of the observation period (Week -4) being within 10.0%\\* of the value at 4 weeks after the initiation of the observation period (Week -8) (\\*rounded off to the first decimal place).\n4. Was receiving specific diet and exercise (if any) therapies during the observation period.\n\nExclusion Criteria:\n\n1. Had taken other diabetic medications than metformin within 12 weeks before the initiation of the treatment period (Week 0).\n2. With a history or symptoms of lactic acidosis.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "26 Years", "maximumAge": "64 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Professor, Diabetes and Endocrine Division", "affiliation": "Department of Medicine, Kawasaki Medical School", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants with a historical diagnosis of type 2 diabetes mellitus with uncontrolled blood glucose despite treatment with metformin as well as diet and exercise were enrolled in one of 3, once-daily (QD), twice daily (BID) or three times daily (TID) treatment groups.", "recruitmentDetails": "Participants enrolled at 30 investigative sites in Japan from 22 August 2008 to 28 April 2009.", "groups": [{"id": "FG000", "title": "Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "FG001", "title": "Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "FG002", "title": "Metformin 500mg BID or 750mg TID", "description": "Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "92"}, {"groupId": "FG001", "numSubjects": "96"}, {"groupId": "FG002", "numSubjects": "100"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "91"}, {"groupId": "FG001", "numSubjects": "93"}, {"groupId": "FG002", "numSubjects": "100"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Schedule Conflict", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "BG001", "title": "Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "BG002", "title": "Metformin 500mg BID or 750mg TID", "description": "Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "92"}, {"groupId": "BG001", "value": "96"}, {"groupId": "BG002", "value": "100"}, {"groupId": "BG003", "value": "288"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.4", "spread": "8.80"}, {"groupId": "BG001", "value": "52.3", "spread": "8.02"}, {"groupId": "BG002", "value": "52.1", "spread": "8.05"}, {"groupId": "BG003", "value": "52.6", "spread": "8.28"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "90"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "60"}, {"groupId": "BG001", "value": "66"}, {"groupId": "BG002", "value": "72"}, {"groupId": "BG003", "value": "198"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 12).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.", "populationDescription": "Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 12.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG001", "title": "Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG002", "title": "Metformin 500mg BID or 750mg TID", "description": "Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "96"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.54", "spread": "0.562"}, {"groupId": "OG001", "value": "-0.64", "spread": "0.488"}, {"groupId": "OG002", "value": "0.21", "spread": "0.641"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.751", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.923", "ciUpperLimit": "-0.579"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.858", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.019", "ciUpperLimit": "-0.697"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 2).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 2.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG001", "title": "Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG002", "title": "Metformin 500mg BID or 750mg TID", "description": "Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "96"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.13", "spread": "0.196"}, {"groupId": "OG001", "value": "-0.13", "spread": "0.150"}, {"groupId": "OG002", "value": "0.06", "spread": "0.197"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.191", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.247", "ciUpperLimit": "-0.135"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.192", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.242", "ciUpperLimit": "-0.143"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 4).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 4.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG001", "title": "Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG002", "title": "Metformin 500mg BID or 750mg TID", "description": "Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "96"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.29", "spread": "0.279"}, {"groupId": "OG001", "value": "-0.31", "spread": "0.268"}, {"groupId": "OG002", "value": "0.09", "spread": "0.302"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Hazard Ratio, log", "paramValue": "-0.386", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.469", "ciUpperLimit": "-0.303"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.403", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.484", "ciUpperLimit": "-0.323"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (Week 8).", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.", "populationDescription": "Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Glycosylated Hemoglobin", "timeFrame": "Baseline and Week 8.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG001", "title": "Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG002", "title": "Metformin 500mg BID or 750mg TID", "description": "Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "96"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.49", "spread": "0.488"}, {"groupId": "OG001", "value": "-0.56", "spread": "0.404"}, {"groupId": "OG002", "value": "0.13", "spread": "0.465"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.621", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.757", "ciUpperLimit": "-0.486"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Hazard Ratio, log", "paramValue": "-0.692", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.814", "ciUpperLimit": "-0.569"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (Week 2).", "description": "The change between the value of fasting plasma glucose collected at week 2 and baseline.", "populationDescription": "Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 2.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG001", "title": "Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG002", "title": "Metformin 500mg BID or 750mg TID", "description": "Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "95"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-19.2", "spread": "21.10"}, {"groupId": "OG001", "value": "-23.2", "spread": "24.17"}, {"groupId": "OG002", "value": "0.0", "spread": "26.37"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-19.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.12", "ciUpperLimit": "-12.40"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-23.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.43", "ciUpperLimit": "-16.12"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (Week 4).", "description": "The change between the value of fasting plasma glucose collected at week 4 and baseline.", "populationDescription": "Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 4.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG001", "title": "Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG002", "title": "Metformin 500mg BID or 750mg TID", "description": "Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "96"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-19.8", "spread": "25.28"}, {"groupId": "OG001", "value": "-23.5", "spread": "26.05"}, {"groupId": "OG002", "value": "-2.2", "spread": "23.37"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-17.60", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-24.54", "ciUpperLimit": "-10.66"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-21.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.32", "ciUpperLimit": "-14.39"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (Week 8).", "description": "The change between the value of fasting plasma glucose collected at week 8 and baseline.", "populationDescription": "Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 8.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG001", "title": "Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG002", "title": "Metformin 500mg BID or 750mg TID", "description": "Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "96"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-22.0", "spread": "23.05"}, {"groupId": "OG001", "value": "-21.3", "spread": "25.30"}, {"groupId": "OG002", "value": "-3.1", "spread": "26.23"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-18.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.95", "ciUpperLimit": "-11.79"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-18.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.43", "ciUpperLimit": "-10.90"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (Week 12).", "description": "The change between the value of fasting plasma glucose collected at week 12 or final visit and baseline.", "populationDescription": "Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 12.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG001", "title": "Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG002", "title": "Metformin 500mg BID or 750mg TID", "description": "Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "96"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-19.0", "spread": "23.23"}, {"groupId": "OG001", "value": "-23.1", "spread": "27.84"}, {"groupId": "OG002", "value": "-0.8", "spread": "32.20"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-18.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.32", "ciUpperLimit": "-10.16"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-22.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.87", "ciUpperLimit": "-13.88"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).", "description": "The change between the value of blood glucose measured by the meal tolerance test collected at week 12 or final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.", "populationDescription": "Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 12.", "groups": [{"id": "OG000", "title": "Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG001", "title": "Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks."}, {"id": "OG002", "title": "Metformin 500mg BID or 750mg TID", "description": "Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "94"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "61.7", "spread": "43.42"}, {"groupId": "OG001", "value": "64.2", "spread": "34.76"}, {"groupId": "OG002", "value": "70.6", "spread": "35.31"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.89", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.14", "ciUpperLimit": "2.37"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.34", "ciUpperLimit": "3.52"}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Treatment-emergent adverse events are any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after receiving the last dose of study drug.", "description": "At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.", "eventGroups": [{"id": "EG000", "title": "Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 92, "otherNumAffected": 32, "otherNumAtRisk": 92}, {"id": "EG001", "title": "Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID", "description": "Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.", "seriousNumAffected": 2, "seriousNumAtRisk": 96, "otherNumAffected": 37, "otherNumAtRisk": 96}, {"id": "EG002", "title": "Metformin 500mg BID or 750mg TID", "description": "Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 100, "otherNumAffected": 29, "otherNumAtRisk": 100}], "seriousEvents": [{"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 100}]}, {"term": "Mallory-Weiss syndrome", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 100}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 96}, {"groupId": "EG002", "numAffected": 20, "numAtRisk": 100}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 96}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 100}]}, {"term": "Conjunctivitis allergic", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 96}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 100}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 96}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 100}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 100}]}, {"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 96}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 100}]}, {"term": "Hepatic steatosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 96}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 100}]}, {"term": "Blood lactic acid increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 100}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited."}, "pointOfContact": {"title": "General Manager", "organization": "Japan Development Center, Pharmaceutical Development Division", "email": "clinicaltrialregistry@tpna.com", "phone": "+81-6-6204-5257"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000520853", "term": "Alogliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M247106", "name": "Alogliptin", "asFound": "Reflex", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}